Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1951 2
1953 1
1955 2
1956 2
1957 2
1960 1
1978 6
1979 6
1980 14
1981 17
1982 22
1983 21
1984 15
1985 18
1986 21
1987 25
1988 33
1989 38
1990 42
1991 42
1992 39
1993 40
1994 36
1995 45
1996 49
1997 39
1998 44
1999 53
2000 67
2001 73
2002 56
2003 55
2004 58
2005 77
2006 61
2007 66
2008 57
2009 52
2010 68
2011 51
2012 64
2013 67
2014 80
2015 63
2016 53
2017 54
2018 74
2019 63
2020 52
2021 63
2022 59
2023 53
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

1,992 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean cedar (38,692 results)?
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, Abergel A, Debette-Gratien M, Larrey D, Roux O, Bronowicki JP, Boursier J, de Ledinghen V, Heurgue-Berlot A, Nguyen-Khac E, Zoulim F, Ollivier-Hourmand I, Zarski JP, Nkontchou G, Lemoinne S, Humbert L, Rainteau D, Lefèvre G, de Chaisemartin L, Chollet-Martin S, Gaouar F, Admane FH, Simon T, Poupon R. Corpechot C, et al. N Engl J Med. 2018 Jun 7;378(23):2171-2181. doi: 10.1056/NEJMoa1714519. N Engl J Med. 2018. PMID: 29874528 Free article. Clinical Trial.
RESULTS: The primary outcome occurred in 31% of the patients assigned to bezafibrate and in 0% assigned to placebo (difference, 31 percentage points; 95% confidence interval, 10 to 50; P<0.001). ...Two patients in each group had complications from end-stage liver diseas …
RESULTS: The primary outcome occurred in 31% of the patients assigned to bezafibrate and in 0% assigned to placebo (difference, 31 pe …
Bezafibrat als Hilfe gegen Pruritus.
Lutz HH, Tischendorf J. Lutz HH, et al. MMW Fortschr Med. 2021 Oct;163(17):32-34. doi: 10.1007/s15006-021-0383-9. MMW Fortschr Med. 2021. PMID: 34595636 Review. German. No abstract available.
Bezafibrate.
[No authors listed] [No authors listed] Drug Ther Bull. 1983 Sep 23;21(19):75-6. Drug Ther Bull. 1983. PMID: 6628234 No abstract available.
Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer.
Tanaka K, Chamoto K, Saeki S, Hatae R, Ikematsu Y, Sakai K, Ando N, Sonomura K, Kojima S, Taketsuna M, Kim YH, Yoshida H, Ozasa H, Sakamori Y, Hirano T, Matsuda F, Hirai T, Nishio K, Sakagami T, Fukushima M, Nakanishi Y, Honjo T, Okamoto I. Tanaka K, et al. Sci Transl Med. 2022 Dec 14;14(675):eabq0021. doi: 10.1126/scitranslmed.abq0021. Epub 2022 Dec 14. Sci Transl Med. 2022. PMID: 36516270
We have therefore now performed a phase 1 trial (UMIN000017854) of bezafibrate with nivolumab in previously treated patients with advanced non-small cell lung cancer. ...Preplanned comprehensive analysis of plasma metabolites and gene expression in peripheral cytotoxic T c …
We have therefore now performed a phase 1 trial (UMIN000017854) of bezafibrate with nivolumab in previously treated patients with adv …
Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.
de Vries E, Bolier R, Goet J, Parés A, Verbeek J, de Vree M, Drenth J, van Erpecum K, van Nieuwkerk K, van der Heide F, Mostafavi N, Helder J, Ponsioen C, Oude Elferink R, van Buuren H, Beuers U; Netherlands Association for the Study of the Liver-Cholestasis Working Group. de Vries E, et al. Gastroenterology. 2021 Feb;160(3):734-743.e6. doi: 10.1053/j.gastro.2020.10.001. Epub 2020 Oct 5. Gastroenterology. 2021. PMID: 33031833 Clinical Trial.
Patients received once-daily bezafibrate (400 mg) or placebo for 21 days. The primary end point was 50% reduction of pruritus (VAS; intention-to-treat). ...Serum bile acids and autotaxin activity remained unchanged. Serum creatinine levels tended to mildly increase (3% …
Patients received once-daily bezafibrate (400 mg) or placebo for 21 days. The primary end point was 50% reduction of pruritus (VAS; i …
Treatment of Primary Biliary Cholangitis: First-Line and Second-Line Therapies.
Liu CH, Bowlus CL. Liu CH, et al. Clin Liver Dis. 2022 Nov;26(4):705-726. doi: 10.1016/j.cld.2022.06.012. Epub 2022 Sep 14. Clin Liver Dis. 2022. PMID: 36270725 Review.
Obeticholic acid has been conditionally approved for the treatment of PBC as add-on therapy and bezafibrate has shown similar efficacy in this group of patients. Several new therapies are in development and may further add to the treatment options available to patients wit …
Obeticholic acid has been conditionally approved for the treatment of PBC as add-on therapy and bezafibrate has shown similar efficac …
Evaluation and Management of Pruritus in Primary Biliary Cholangitis.
Düll MM, Kremer AE. Düll MM, et al. Clin Liver Dis. 2022 Nov;26(4):727-745. doi: 10.1016/j.cld.2022.06.009. Clin Liver Dis. 2022. PMID: 36270726 Free article. Review.
Efficient therapy consists of topical treatment combined with systemic options such as anion exchangers, rifampicin, bezafibrate, mu-opioid receptor antagonists, selective-serotonin receptor uptake inhibitors, and gabapentinoids. ...
Efficient therapy consists of topical treatment combined with systemic options such as anion exchangers, rifampicin, bezafibrate, mu- …
1,992 results